This is an early-stage pipeline event with no near-term revenue impact. Monitor for safety readouts and enrollment updates from the Phase 1 trial, which will determine whether the autoimmune platform has clinical proof of concept.
Price Chart
Executive Summary
Immunocore dosed the first patient in a Phase 1 trial of IMC-S118AI, its first tissue-specific autoimmune candidate for type 1 diabetes. This is an early clinical milestone with no safety or efficacy data yet, and the trial is dose-escalation only.
Key Facts
- First patient dosed in Phase 1 trial (NCT07493122) of IMC-S118AI for HLA-A*02:01-positive type 1 diabetes patients
- IMC-S118AI is a bispecific molecule with a PD-1 agonist effector arm designed to down-modulate autoreactive T cells in a tissue-specific manner
- Preclinical data published in Science Advances demonstrated selective binding to beta cells and suppression of autoreactive T cell activity in human pancreas tissue slices
- The trial is a first-in-human, dose-escalation study evaluating safety, pharmacokinetics, and clinical activity
Financial Impact
No financial data provided; early clinical milestone with no revenue or cost figures disclosed
Risk Factors
- Phase 1 dose-escalation trials have high failure rates; safety or efficacy issues could halt development
- No clinical data yet; preclinical results may not translate to humans
- Type 1 diabetes is a competitive space with established therapies (insulin) and emerging immune-modulating treatments
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3381501 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | Press Release | $29.48 | awaiting T+60 | — | $31.96 (+8.41%) |
Oct 7, 2026 20d ago | SC 13G/A | $29.41 | awaiting T+60 | — | $31.96 (+8.67%) |
Sep 14, 2026 6w ago | 8-K | $32.46 | awaiting T+60 | — | $31.96 (−1.54%) |
Aug 6, 2026 11w ago | 8-K | $34.50 | awaiting T+60 | — | $31.96 (−7.36%) |
May 31, 2026 21w ago | Press Release | $29.13 $37.40 | ▲ +28.39% | ▲ +27.16% | $31.96 (+9.72%) |
Apr 19, 2026 27w ago | Press Release | $31.46 $34.68 | ▲ +10.24% | ▲ +3.46% | $31.96 (+1.59%) |
Apr 8, 2026 28w ago | 144 | $31.85 $32.50 | ▲ +2.04% | ▼ −8.42% | $31.96 (+0.35%) |
Mar 17, 2026 32w ago | Press Release | $30.04 $28.62 | ▼ −4.73% | ▼ −16.25% | $31.96 (+6.39%) |
Feb 25, 2026 34w ago | 8-K | $32.16 $29.54 | ▼ −8.15% | ▼ −15.10% | $31.96 (−0.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers